Xilio's Losses Mount Amid R&D Spend, Cash Position Boosted by Offering

TL;DR

**Xilio's cash infusion is a temporary fix; recurring losses and going concern warnings mean this is a high-risk bet on unproven pipeline assets.**

AI Summary

Xilio Therapeutics, Inc. reported a net loss of $15.844 million for the three months ended June 30, 2025, an increase from $13.925 million in the same period of 2024. For the six months ended June 30, 2025, the net loss was $29.109 million, compared to $31.128 million in the prior year. Revenue from collaboration and license agreements significantly increased to $8.084 million for the three months ended June 30, 2025, up from $2.357 million in 2024, and to $11.014 million for the six months, also up from $2.357 million. Research and development expenses rose to $15.330 million for the quarter, from $11.216 million, and general and administrative expenses increased to $7.120 million from $5.815 million. The company's cash and cash equivalents increased substantially to $121.551 million as of June 30, 2025, from $55.291 million at December 31, 2024, primarily due to a June 2025 follow-on public offering and common stock issuances. A significant risk highlighted is the 'substantial doubt regarding our ability to continue as a going concern' due to recurring losses, necessitating additional capital or cost reduction strategies. The company also issued common stock warrants in connection with the June 2025 offering, with a liability of $38.550 million recorded.

Why It Matters

Xilio's increased cash reserves to $121.551 million, largely from a recent public offering, provide a critical lifeline for its early-stage drug development, but the persistent net losses and 'going concern' warning signal high operational risk for investors. The significant jump in collaboration revenue to $11.014 million indicates potential validation of its pipeline, yet R&D expenses also climbed, reflecting the costly nature of biotech. For employees, continued funding means job security and progress on therapeutic candidates, while customers (future patients) depend on successful clinical trials. In a competitive biotech landscape, Xilio's ability to convert its cash runway into clinical milestones will determine its long-term viability and market position.

Risk Assessment

Risk Level: high — The filing explicitly states, "Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern." This is a critical red flag, indicating severe financial instability. Despite an increase in cash to $121.551 million, the company continues to incur significant net losses, reaching $29.109 million for the six months ended June 30, 2025, demonstrating a high burn rate relative to its current capital.

Analyst Insight

Investors should approach Xilio Therapeutics with extreme caution, recognizing the significant 'going concern' risk. Monitor closely for updates on clinical trial progress and further capital raises, as these will be critical determinants of the company's survival. Consider this a highly speculative investment, suitable only for those with a high-risk tolerance.

Financial Highlights

debt To Equity

17.93

revenue

$11.014M

operating Margin

-256.2%

total Assets

$133.813M

total Debt

$126.744M

net Income

$ -29.109M

eps

$ -0.34

gross Margin

N/A

cash Position

$121.551M

revenue Growth

+365.7%

Revenue Breakdown

Key Numbers

• $121.551M — Cash and Cash Equivalents (Increased from $55.291M at Dec 31, 2024, providing a longer runway but still facing 'going concern' risk.)
• $29.109M — Net Loss (Six Months) (Represents the accumulated deficit for the first half of 2025, indicating continued unprofitability.)
• $11.014M — Collaboration and License Revenue (Six Months) (Significant increase from $2.357M in 2024, showing progress in partnership agreements.)
• $23.596M — Research and Development Expenses (Six Months) (Increased from $21.616M in 2024, reflecting ongoing investment in pipeline development.)
• $38.550M — Common Stock Warrant Liabilities (New liability from June 2025 follow-on public offering, representing potential future dilution or cash outflow.)
• 51,827,910 — Common Shares Outstanding (As of August 8, 2025, indicating increased share count from recent offerings.)

Key Players & Entities

• Xilio Therapeutics, Inc. (company) — registrant of the 10-Q filing
• Nasdaq Global Select Market (regulator) — exchange where XLO common stock is registered
• AbbVie Group Holdings Limited (company) — collaboration agreement partner
• Gilead Sciences, Inc. (company) — license agreement partner
• F. Hoffmann-La Roche Ltd (company) — clinical collaboration partner
• WuXi Biologics (Hong Kong) Limited (company) — third-party for research, development, and manufacturing activities in China
• $121.551 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $55.291 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $15.844 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $29.109 million (dollar_amount) — net loss for the six months ended June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has recurring losses and a history of operating deficits, leading to substantial doubt about its ability to continue as a going concern. This necessitates future financing or cost-saving measures to sustain operations.
• Warrant Liability [medium — financial]: A new liability of $38.550 million was recorded for common stock warrants issued in connection with the June 2025 follow-on public offering. This represents potential future dilution or cash outflow.
• Research and Development Expenses [medium — operational]: R&D expenses increased to $15.330 million for the three months ended June 30, 2025, and $23.596 million for the six months. Continued investment is required for pipeline development, impacting near-term profitability.
• General and Administrative Expenses [medium — operational]: G&A expenses rose to $7.120 million for the quarter and $15.635 million for the six months. Increased operational scale and public company requirements contribute to higher G&A costs.

Industry Context

Xilio Therapeutics operates in the biotechnology sector, focusing on developing immuno-oncology therapies. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success often depends on clinical trial outcomes and securing partnerships or further funding.

Regulatory Implications

As a clinical-stage biotechnology company, Xilio Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet regulatory requirements, or adverse findings can significantly impact development timelines and the potential for market approval.

What Investors Should Do

1. Monitor R&D expenditure trends and clinical trial progress for pipeline development updates.
2. Analyze the impact of the common stock warrant liabilities on future dilution and cash flow.
3. Assess the company's ability to secure additional capital or implement cost-saving measures to address the 'going concern' risk.
4. Evaluate the sustainability of the increased collaboration and license revenue as a key driver of financial performance.

Key Dates

• 2025-06-30: End of Second Quarter — Reporting period for the 10-Q, showing increased cash reserves and significant revenue growth from collaborations, but also a substantial warrant liability.
• 2025-06-01: Follow-on Public Offering — Primary driver for the increase in cash to $121.551M. Also resulted in the issuance of common stock warrants, creating a new liability of $38.550M.
• 2025-06-30: Balance Sheet Date — Shows total assets of $133.813M and total liabilities of $126.744M, with a significant portion of liabilities being deferred revenue and warrant liabilities.

Glossary

Deferred revenue

Revenue that has been received by the company but not yet earned. It represents obligations to provide goods or services in the future. (The company has significant deferred revenue ($42.278M current portion and $28.632M non-current) which is expected to be recognized as revenue in future periods, potentially improving future financial results.)

Common stock warrant liabilities

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. When issued in connection with financing, they can be classified as liabilities. (A new liability of $38.550M was recorded, impacting the balance sheet and representing potential future dilution or cash outflow if exercised.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (Xilio Therapeutics has disclosed substantial doubt regarding its ability to continue as a going concern due to recurring losses, highlighting a significant financial risk.)

Accumulated deficit

The cumulative net losses of a company since its inception, less any net gains. It represents the total loss that has not been offset by profits. (The accumulated deficit was $(412.862M) as of June 30, 2025, indicating the company's history of unprofitability.)

Year-Over-Year Comparison

Compared to the prior year, Xilio Therapeutics has seen a significant increase in revenue from collaboration and license agreements, more than tripling for both the three and six-month periods. However, operating expenses, particularly R&D and G&A, have also risen, leading to a wider net loss for the quarter ($15.844M vs $13.925M) but a narrower loss for the six-month period ($29.109M vs $31.128M). The company's cash position has substantially improved due to a recent public offering, but a new significant warrant liability has been introduced.

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
• $100.0 million — Gilead; the potential receipt of up to $100.0 million in additional gross proceeds from the e

Filing Documents

• xlo-20250630x10q.htm (10-Q) — 2126KB
• xlo-20250630xex3d1.htm (EX-3.1) — 79KB
• xlo-20250630xex31d1.htm (EX-31.1) — 13KB
• xlo-20250630xex31d2.htm (EX-31.2) — 13KB
• xlo-20250630xex32d1.htm (EX-32.1) — 8KB
• 0001558370-25-011477.txt ( ) — 7399KB
• xlo-20250630.xsd (EX-101.SCH) — 52KB
• xlo-20250630_cal.xml (EX-101.CAL) — 33KB
• xlo-20250630_def.xml (EX-101.DEF) — 244KB
• xlo-20250630_lab.xml (EX-101.LAB) — 426KB
• xlo-20250630_pre.xml (EX-101.PRE) — 366KB
• xlo-20250630x10q_htm.xml (XML) — 1005KB

Financial Statements (unaudited)

Financial Statements (unaudited) 7 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 7 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 8 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 11 Notes to Condensed Consolidated Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 42 Part II Other Information 43 Item 1A.

Risk Factors

Risk Factors 43 Item 5. Other Information 114 Item 6. Exhibits 115

Signatures

Signatures 116 6 Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements XILIO THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) June 30, December 31, 2025 2024 ASSETS Current assets Cash and cash equivalents $ 121,551 $ 55,291 Prepaid expenses and other current assets 2,165 4,943 Total current assets 123,716 60,234 Restricted cash 1,794 1,782 Property and equipment, net 4,018 4,472 Operating lease right-of-use asset 4,285 4,587 Total assets $ 133,813 $ 71,075 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 4,097 $ 2,574 Accrued expenses 5,621 9,981 Deferred revenue, current portion 42,278 13,518 Operating lease liability, current portion 1,264 1,188 Total current liabilities 53,260 27,261 Deferred revenue, net of current portion 28,632 19,262 Operating lease liability, net of current portion 6,302 6,954 Common stock warrant liabilities 38,550 — Total liabilities 126,744 53,477 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, $ 0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.0001 par value; 600,000,000 shares authorized at June 30, 2025 and 200,000,000 shares authorized at December 31, 2024; 51,827,910 shares issued and outstanding at June 30, 2025; 45,756,773 shares issued and outstanding at December 31, 2024 5 5 Additional paid-in capital 419,926 401,346 Accumulated deficit ( 412,862 ) ( 383,753 ) Total stockholders' equity 7,069 17,598 Total liabilities and stockholders' equity $ 133,813 $ 71,075 The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents XILIO THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) (Unaudited) Three Months Ended J

View Full Filing

View this 10-Q filing on SEC EDGAR